mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company

Daily Archives: 29.09.2016

Home > News > Daily Archives: 29.09.2016

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma

29.09.2016 by in category News

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma Eleventa Ltd. (Moscow, Russia), a portfolio company of Maxwell Biotech Venture Fund (MBVF), and its development partner, Oxagen Limited (Abingdon, UK), today announced the completion of patient enrollment in the a Phase 3 clinical […]

0 0 Read more

 

© Eleventa, 2012—2020